- Home
- VRTX
as 07-26-2024 4:00pm EST
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Upcoming Earnings Alert:
Get ready for potential market movements as Vertex Pharmaceuticals Incorporated VRTX prepares to release earnings report on 01 Aug 2024.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 122.6B | IPO Year: | 1991 |
| Target Price: | $472.33 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 25 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 15.41 | EPS Growth: | 22.79 |
| 52 Week Low/High: | $340.20 - $503.99 | Next Earning Date: | 08-01-2024 |
| Revenue: | $10,185,000,000 | Revenue Growth: | 10.61% |
| Revenue Growth (this year): | 11.14% | Revenue Growth (next year): | 8.71% |
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bozic Carmen | VRTX | EVP and CMO | Jul 10 '24 | Sell | $487.34 | 2,280 | $1,111,135.20 | 27,819 | SEC Form 4 |
| Bozic Carmen | VRTX | EVP and CMO | Jun 26 '24 | Sell | $471.72 | 2,280 | $1,075,521.60 | 30,099 | SEC Form 4 |
| Bozic Carmen | VRTX | EVP and CMO | Jun 12 '24 | Sell | $478.00 | 2,280 | $1,089,840.00 | 32,379 | SEC Form 4 |
| Atkinson Edward Morrow III | VRTX | EVP, Chief Technical Ops. Off. | Jun 11 '24 | Sell | $478.00 | 7,288 | $3,483,664.00 | 15,972 | SEC Form 4 |
| WAGNER CHARLES F JR | VRTX | EVP & Chief Financial Officer | Jun 3 '24 | Sell | $460.00 | 3,250 | $1,495,000.00 | 47,137 | SEC Form 4 |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Jun 3 '24 | Sell | $460.00 | 2,175 | $1,000,500.00 | 49,098 | SEC Form 4 |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | May 30 '24 | Sell | $439.11 | 2,350 | $1,031,908.50 | 53,523 | SEC Form 4 |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | May 30 '24 | Sell | $445.00 | 2,250 | $1,001,250.00 | 51,273 | SEC Form 4 |
| Bozic Carmen | VRTX | EVP and CMO | May 29 '24 | Sell | $445.56 | 2,280 | $1,015,876.80 | 34,659 | SEC Form 4 |
| WAGNER CHARLES F JR | VRTX | EVP & Chief Financial Officer | May 28 '24 | Sell | $454.79 | 3,250 | $1,478,067.50 | 50,387 | SEC Form 4 |
| Kewalramani Reshma | VRTX | CEO & President | May 24 '24 | Sell | $457.00 | 1,565 | $715,205.00 | 121,374 | SEC Form 4 |
| SACHS BRUCE I | VRTX | Director | May 22 '24 | Sell | $448.00 | 7,073 | $3,168,704.00 | 40,000 | SEC Form 4 |
| Kewalramani Reshma | VRTX | CEO & President | May 20 '24 | Sell | $447.00 | 15,202 | $6,795,294.00 | 121,374 | SEC Form 4 |
| Arbuckle Stuart A | VRTX | EVP, COO | May 15 '24 | Sell | $430.93 | 69 | $29,734.17 | 49,691 | SEC Form 4 |
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | May 15 '24 | Sell | $430.93 | 54 | $23,270.22 | 25,813 | SEC Form 4 |
| Sachdev Amit | VRTX | EVP Chief Patient & Ext Af Off | May 15 '24 | Sell | $430.93 | 32 | $13,789.76 | 55,325 | SEC Form 4 |
| Ambrose Kristen | VRTX | SVP & Chief Accounting Officer | Apr 1 '24 | Sell | $419.00 | 240 | $100,560.00 | 7,500 | SEC Form 4 |
| ALTSHULER DAVID | VRTX | EVP, Global Research and CSO | Feb 23 '24 | Sell | $425.70 | 4,239 | $1,804,542.30 | 25,813 | SEC Form 4 |
| Arbuckle Stuart A | VRTX | EVP, COO | Feb 23 '24 | Sell | $425.70 | 5,034 | $2,142,973.80 | 49,691 | SEC Form 4 |
| Ambrose Kristen | VRTX | SVP & Chief Accounting Officer | Feb 23 '24 | Sell | $425.70 | 883 | $375,893.10 | 7,965 | SEC Form 4 |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Feb 23 '24 | Sell | $425.70 | 354 | $150,697.80 | 55,804 | SEC Form 4 |
| Sachdev Amit | VRTX | EVP Chief Patient & Ext Af Off | Feb 23 '24 | Sell | $425.70 | 3,004 | $1,278,802.80 | 55,325 | SEC Form 4 |
| Atkinson Edward Morrow III | VRTX | EVP, Chief Technical Ops. Off. | Feb 23 '24 | Sell | $425.70 | 883 | $375,893.10 | 15,972 | SEC Form 4 |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Feb 21 '24 | Sell | $421.77 | 360 | $151,837.20 | 59,467 | SEC Form 4 |
| ALTSHULER DAVID | VRTX | EVP, Global Research and CSO | Feb 21 '24 | Sell | $421.77 | 3,002 | $1,266,153.54 | 34,022 | SEC Form 4 |
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
MT Newswires
11 hours ago
Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $502 From $458
Zacks
11 hours ago
Twist Bioscience (TWST) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
GuruFocus.com
a day ago
Insider Sale at Vertex Pharmaceuticals Inc (VRTX) by EVP and CMO Carmen Bozic
GuruFocus.com
a day ago
Baillie Gifford's Strategic Moves in Q2 2024: A Closer Look at NVIDIA Corp's Impact
Motley Fool
2 days ago
Is Vertex Pharmaceuticals' Monopoly in Danger?
Motley Fool
2 days ago
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
GuruFocus.com
2 days ago
Insider Sale: CEO & President Reshma Kewalramani Sells 15,202 Shares of Vertex ...
Zacks
2 days ago
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
Compare VRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRTX Vertex Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.